WASHINGTON--(BUSINESS WIRE)-- A record 887 medicines for various of cancers are in clinical trials or awaiting Food and Drug Administration (FDA) review—well over double the number in the pipeline just six years ago, according to a report unveiled today by the Pharmaceutical Research and Manufacturers of America (PhRMA).
When PhRMA released its first accounting of medicines in development for cancer in 1988, only 65 were recorded. The numbers over the next decade grew gradually. As recently as 2005, there were fewer than 400 medicines in development for cancer.
“Unprecedented insights into how cancer cells develop, grow and spread are providing new targets and new ways of attacking the disease,” said John J. Castellani, PhRMA’s president and CEO, explaining the increase. “Rapidly advancing technologies and the commitment of researchers to follow new clues are providing hope.”
One promising development is the increased understanding about the many ways a tumor can protect and feed itself by co-opting the body’s own mechanisms, for example by reducing the efficacy of the immune system and by proliferating the growth of blood vessels, said Garry Neil, M.D., corporate vice president of science and technology at Johnson & Johnson. Dr. Neil is also chair of PhRMA’s Science and Regulatory Affairs Executive Committee.
Other remarkable new developments in cancer research include a better understanding of the key role that cancer stem cells play in resistance to chemotherapy, and the interplay between cancer cells and the supporting tissue that surround them, said Scott Waldman, M.D., Ph.D., of the Kimmel Cancer Center.
Biomarkers, Waldman added, are increasing researchers’ ability to predict and to understand the body’s response to new therapies. [related video] Dr. Waldman was recognized this year by the PhRMA Foundation for his breakthrough work on colorectal cancer.
He and Dr. Neil also pointed to advanced gene sequencing that is revealing the genetic basis of cancer and leading to opportunities for personalized medicine. Not only has genetic sequencing become available to many more researchers, but it has advanced into “next generation” and “multiplexed deep sequencing.”
Combination therapies, which were so successful in fighting HIV/AIDS, also represent an important step in cancer treatment, said Dr. Neil.
“As we develop the ability to block, with precision, the drivers of tumor growth, we must also block the escape mechanisms facilely used by these cells,” Neil said. Regulatory agencies, he added, are recognizing the need to simplify the testing of multiple medicines in development in order to realize this potential breakthrough.
Although five-year survival rates have increased across cancers since 1975—and have increased dramatically for breast, prostate, colon, rectum and lung cancer—the disease remains a leading cause of death.
Asked where we now stand in the battle against cancer, Dr. Neil quoted Winston Churchill, speaking in the late fall of 1942: “This is not the end. It is not even the beginning of the end…”
However, against a backdrop of new tools and a scientifically-based set of rules, Dr. Neil added, “We are hopefully moving to the beginning of the end for many cancers.”
You can view the related video at: http://www.youtube.com/watch?v=k4os7s9pfrY
Embed codes are available for posting to your website:
<iframe title="YouTube video player" width="640" height="390" src="http://www.youtube.com/embed/k4os7s9pfrY?rel=0" frameborder="0" allowfullscreen></iframe>
Link to report: http://www.phrma.org/sites/default/files/1000/medicinesindevelopmentcancer2011_0.pdf
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. PhRMA companies are leading the way in the search for new cures. PhRMA members alone invested an estimated $49.4 billion in 2010 in discovering and developing new medicines. Industry-wide research and investment reached a record $67.4 billion in 2010.
Find PhRMA Online:
- Website – http://www.phrma.org
- facebook – www.facebook.com/PhRMA
- Blog – www.phrma.org/catalyst
- Twitter – www.Twitter.com/PhRMA and www.Twitter.com/PhRMApress
- YouTube – www.youtube.com/PhRMApress
For information on how innovative medicines save lives, visit: http://www.innovation.org
For information on the Partnership for Prescription Assistance, visit: http://www.pparx.org
For information on ensuring the flow of medicines during public health emergencies, visit http://www.rxresponse.org
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6672342&lang=en
Pharmaceutical Research and Manufacturers of America (PhRMA)
Cindy Loose, 202-835-3460
KEYWORDS: United States North America District of Columbia
INDUSTRY KEYWORDS: Seniors Women Health Biotechnology Clinical Trials Genetics Public Policy/Government Healthcare Reform Oncology Pharmaceutical Radiology Other Policy Issues Public Policy White House/Federal Government Children Research FDA Consumer African-American Family Science Hispanic General Health Men